临床上 PSA 相关指标如下: 总 PSA(t PSA,total PSA):即血液中游离态 PSA 和复 合态 PSA 的总和.1986 年,Hybritech 公司在对一组无前列腺 癌男性进行研究后,首次提出了传统的临界值 4.0 μg/L[5].这是 FDA 批准的第一次 PSA 试验[6].因此,确定 PSA 值 > 4.0 μg/L 用于推荐活检,尽管已知男性...
The present prospective work, reports a targeting screening for prostatic carcinoma by determination of total prostate specific antigen and PSA density in Moroccan population and the relationship between this parameters and pathological analysis of prostate biopsy. Blood samples from 236 Moroccan male ...
When your doctor initially tests your prostate-specific antigen (PSA), they look at the total amount of PSA in your blood. If this test shows you have a high PSA level, your doctor may have you take some additional tests to decide if you need aprostate biopsy. ...
PSA test results are not always unambiguous. A total PSA value that is higher than reference values does not always suggest the presence of cancer, while on the other hand, a low PSA level does not exclude the probability of cancer. Therefore, when assessing the entire process, a specialist...
PSA can be found in the blood in two primary forms: Free PSA: It is not bound to any protein Bound PSA: It is bound to other proteins, usually carrier proteins in the blood In most cases, doctors order a total PSA measure. This screening test does not discriminate between free and bou...
PSA velocity.This isn't a separate test, but it looks at the results of more than one total PSA test to see if yourPSA levelis rising and if so, how fast. Complexed PSA.This measures the amount of PSA that is attached to proteins in your blood. It’s not widely used, but it may...
inhibitors, thus affecting the f/t PSA that reflects both free PSA, which in blood circulation consists mostly of proteolytically inactive forms, and total immunoreactive PSA, i.e., both free PSA and PSA complexed to its predominant ligand in blood (α-1-antichymotrypsin/ACT/SERPINA3) (Fig....
在这项正在进行的临床试验的初步报告中,60 745名年龄在50至63岁之间的男性被随机分为受邀接受PSA检测的前列腺癌症筛查、PSA为3.0 ng/mL或更高的患者的4-激肽释放酶小组以及MRI或不受邀接受筛查(对照组)。受邀接受筛查的组与对照组的...
The present prospective work, reports a targeting screening for prostatic carcinoma by determination of total prostate specific antigen and PSA density in Moroccan population and the relationship between this parameters and pathological analysis of prostate biopsy. Blood samples from 236 Moroccan male ...
The invention relates to a bioaffinity assay of prostate-specific antigen (PSA) comprising the measurement of either the concentration of total PSA (PSA-T), the concentration of free form of PSA (PSA-